ClinicalTrials.gg
CompletedNCT06716424Updated Jul 10, 2026

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of iGlarLixi (insulin glargine/lixisenatide) in Type 2 Diabetes, sponsored by Sanofi. Completed at 10 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Sanofi · Phase 4, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 186 studies in Diabetes Mellitus, Type 2 by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Sanofi.

Enrollment
140th of 178
105 · median 334
Started
2025
the only one that year
Phase 4
75 of 186
1 open now
Registered
186th of 186
by date

Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 140th largest by enrollment of the 178 interventional ones that give a count, is the only one that started in 2025, is one of 75 in phase 4, and was the 186th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 186 studies in Diabetes Mellitus, Type 2 by Sanofi is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Diabetes Mellitus, Type 2 by Sanofi, or all of them as a file.
02

Study summary

This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.

Read the detailed description

The study duration will be up to 27 weeks, with a treatment duration approximately 24 weeks.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 diabetes mellitus
  • Soliqua
  • iGlarLixi
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥18 years of age, at the time of signing the
  • Participants with Type 2 Diabetes diagnosed for at least 1 year at the time of screening on treatment with Metformin +/- OADs or basal insulin/GLP-1RA for a minimum period of 6 months prior to screening
  • between ≥ 7.5% and ≤10.5% inclusive, during screening
  • Participant with >= 25 kg/m2 (as per Endocrine Society of India, Ref 12)
  • Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of (WOCBP) OR a WOCBP who agrees to follow the guidance during the intervention period and for at least 1 week after the last dose of study intervention (i.e., until Week 27)
  • Signed informed consent

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Type 1 Diabetes mellitus or any diabetes other than T2DM
  • Prior use of any combination of Basal Insulin + GLP-1 RA Fixed Ratio or Free Combination, Premix Insulin, Basal bolus therapy
  • Basal insulin dose >50 U at screening
  • Any clinically-significant abnormality identified either in medical history or during screening evaluation (e.g., physical examination, laboratory tests, , vital signs) or any AEs during screening period, which in judgment of the Investigator would preclude safe completion of the study or constrains efficacy assessment
  • Known presence of factors that interfere with the measurement (e.g., specific variants, hemolytic anemia) compromising the reliability of HbA1c assessment or medical conditions that affect interpretation of HbA1c results (e.g., blood transfusion or severe blood loss in the last 3 months prior to baseline, any condition that shortens erythrocyte survival)
  • History of severe hypoglycemia requiring emergency room admission or hospitalization within 3 months prior to screening visit
  • Proliferative retinopathy or maculopathy requiring treatment according to the Investigator
  • Use of weight loss drugs (including over-the-counter and herbal medications) within 12 Weeks prior to the screening visit
  • Use of systemic (excluding topical application or inhaled forms) for 2 weeks or more within 8 weeks prior to screening visit
  • Likelihood to require treatment prohibited by the protocol during the study.
  • Exposure to any drugs in the last 4 weeks or 5 half-lives, whichever is longer, prior to screening visit or concomitant enrollment in any other clinical study involving an investigational study treatment
  • Any specific situation during study implementation/course that may raise ethics considerations
  • History of hypoglycemia unawareness
  • Patients with known to lixisenatide, insulin glargine or to any of the inactive ingredients in the formulation
  • History of drug or alcohol abuse within 6 months prior to screening visit

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    iGlarLixi

    iGlarLixi will be administered to study participants subcutaneously

    Drug: iGlarLixi (insulin glargine/lixisenatide)

Interventions

  • DrugiGlarLixi (insulin glargine/lixisenatide)

    iGlarLixi is available as a sterile solution for injection that will be administered to study participants subcutaneously

    Also known as: Soliqua®, Solostar®

06

What researchers measure

Primary outcomes

  1. Percentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)

    Time frame: From Day 1 to Week 25

Secondary outcomes

  1. Mean change in hemoglobin A1c (HbA1c)

    Time frame: From baseline to the end of 6 months

  2. Mean change in fasting plasma glucose (FPG)

    Time frame: From baseline to the end of 3 months and 6 months

  3. Mean change in 2 hours postprandial plasma glucose (PPG)

    Time frame: From baseline to the end of 3 months and 6 months

  4. Mean change in fasting Self-Monitoring Plasma Glucose (SMPG)

    Time frame: From baseline to the end of 3 months and 6 months

  5. Change in mean dose of iGlarLixi

    Time frame: From baseline to the end of 6 months

  6. Effect of iGlarLixi on 7-point Self-Monitoring Plasma Glucose (SMPG) profile

    Time frame: From baseline to the end of 3 months and 6 months

  7. Mean change in bodyweight

    Time frame: From baseline to the end of 6 months

  8. Percentage of participants with at least one hypoglycaemic episode

    Hypoglycaemic episodes: American Diabetes Association (ADA) level 1, 2 or 3

    Time frame: From Day 1 to Week 25

07

Study locations

10 sites
  • Investigational Site Number : 3560009
    Bengaluru, 560054, India
  • Investigational Site Number : 3560007
    Delhi, 110088, India
  • Investigational Site Number : 3560005
    Hyderabad, 500034, India
  • Investigational Site Number : 3560006
    Indore, 452010, India
  • Investigational Site Number : 3560011
    Jaipur, 302020, India
  • Investigational Site Number : 3560003
    Kanpur, 208002, India
  • Investigational Site Number : 3560001
    Kolkata, 700020, India
  • Investigational Site Number : 3560008
    Pune, 411004, India
  • Investigational Site Number: 3560013
    Pune, 411057, India
  • Investigational Site Number : 3560014
    Visakhapatnam, 530040, India
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2026, 17 months.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 17 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 4, 2024
StartActual
Jan 6, 2025
Primary completionActual
Jun 12, 2026
CompletionActual
Jun 12, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06716424
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Jan 6, 2025
Primary completion
Jun 12, 2026
Completion
Jun 12, 2026
Last update
Jul 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion